Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENTA 18 Kaletra once-daily versus twice-daily dosing trial in children with HIV
NL-OMON34553Phase 3Active, not recruiting
- Sponsor
- Penta Foundation
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lopinavir + ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Penta Foundation. Primary endpoints: Confirmed virological rebound above 50 copies/mL over 48 weeks, Pharmacokinetics of twice-daily half-strength lopinavir/ritonavir tablets by body weight and 1 more. Started Jul 2010; status: active, not recruiting.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON34553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34553.